A bug in the resistance to EGFR inhibitors: is there a role for Mycoplasma and cytidine deaminase in reducing the activity of osimertinib in lung cancer patients?

Alessandro Leonetti; Daniela Carbone; Alessandro Gregori; Marcello Tiseo; Godefridus J. Peters; Dongmei Deng; Elisa Giovannetti

doi:https://doi.org/10.1007/s00432-021-03647-x

A bug in the resistance to EGFR inhibitors: is there a role for Mycoplasma and cytidine deaminase in reducing the activity of osimertinib in lung cancer patients?

Alessandro Leonetti, Daniela Carbone, Alessandro Gregori, Marcello Tiseo, Godefridus J. Peters, Dongmei Deng, Elisa Giovannetti

Research output: Contribution to journal › Comment/Letter to the editor › Academic

1 Citation (Scopus)

Original language	English
Pages (from-to)	3135-3137
Number of pages	3
Journal	Journal of Cancer Research and Clinical Oncology
Volume	147
Issue number	10
Early online date	26 Apr 2021
DOIs	https://doi.org/10.1007/s00432-021-03647-x
Publication status	Published - Oct 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

https://doi.org/10.1007/s00432-021-03647-x

Cite this

Leonetti, A., Carbone, D., Gregori, A., Tiseo, M., Peters, G. J., Deng, D., & Giovannetti, E. (2021). A bug in the resistance to EGFR inhibitors: is there a role for Mycoplasma and cytidine deaminase in reducing the activity of osimertinib in lung cancer patients? Journal of Cancer Research and Clinical Oncology, 147(10), 3135-3137. https://doi.org/10.1007/s00432-021-03647-x

@article{d9b3328b8f8447239968311a3f364059,

title = "A bug in the resistance to EGFR inhibitors: is there a role for Mycoplasma and cytidine deaminase in reducing the activity of osimertinib in lung cancer patients?",

author = "Alessandro Leonetti and Daniela Carbone and Alessandro Gregori and Marcello Tiseo and Peters, {Godefridus J.} and Dongmei Deng and Elisa Giovannetti",

note = "Funding Information: MT has been on advisory boards and received speakers{\textquoteright} fees for Astra-Zeneca, Pfizer, Eli-Lilly, BMS, Novartis, Roche, MSD, Boehringer Ingelheim, Otsuka, Takeda, and Pierre Fabre. MT has received research grants from Astra-Zeneca and Boehringer Ingelheim. AL received speakers{\textquoteright} fees for Astra-Zeneca. Funding Information: AL and MT are supported by the AIRC-IG grant# 20,074, AG and EG are supported by the KWF Grant#19,571, GJP and EG are supported by the Polish National Science Center Grant#2018/31/B/NZ7/02,909, DD and EG are supported by Cancer Center Amsterdam Grants 2016 and 2018, EG is supported by the AIRC-IG grant#24,444.",

year = "2021",

month = oct,

doi = "https://doi.org/10.1007/s00432-021-03647-x",

language = "English",

volume = "147",

pages = "3135--3137",

journal = "Journal of Cancer Research and Clinical Oncology",

issn = "0171-5216",

publisher = "Springer Verlag",

number = "10",

}

Leonetti, A, Carbone, D, Gregori, A, Tiseo, M, Peters, GJ, Deng, D & Giovannetti, E 2021, 'A bug in the resistance to EGFR inhibitors: is there a role for Mycoplasma and cytidine deaminase in reducing the activity of osimertinib in lung cancer patients?', Journal of Cancer Research and Clinical Oncology, vol. 147, no. 10, pp. 3135-3137. https://doi.org/10.1007/s00432-021-03647-x

A bug in the resistance to EGFR inhibitors: is there a role for Mycoplasma and cytidine deaminase in reducing the activity of osimertinib in lung cancer patients? / Leonetti, Alessandro; Carbone, Daniela; Gregori, Alessandro et al.
In: Journal of Cancer Research and Clinical Oncology, Vol. 147, No. 10, 10.2021, p. 3135-3137.

Research output: Contribution to journal › Comment/Letter to the editor › Academic